

May 24, 2022



CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

HOUSTON, May 24, 2022 /PRNewswire/ -- [CNS Pharmaceuticals, Inc.](#) (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that [John Climaco](#), Chief Executive Officer of CNS Pharmaceuticals, will be participating at the [H.C. Wainwright Global Investment Conference](#) being held May 23-26, 2022 in Miami, FL and virtually.



A [video webcast](#) of Mr. Climaco's presentation is now accessible for viewing on-demand for those registered for the event and will be available on the [Events](#) page in the [Investors](#) section of the Company's website (www.cnspharma.com). The webcast replay will be archived for 90 days following the event.


In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the [conference website](#).

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

For more information, please visit www.CNSPharma.com, and connect with the Company on [Twitter](#), [Facebook](#), and [LinkedIn](#).

 View original content to download multimedia <https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-presentation-at-the-hc-wainwright-global-investment-conference-301553649.html>

SOURCE CNS Pharmaceuticals, Inc.